External Quality Assessment (EQA) program for the preanalytical and analytical immunohistochemical determination of HER2 in breast cancer: An experience on a regional scale

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Terrenato, Irene ^a   Arena, Vincenzo ^c   Pizzamiglio, Sara ^b   Pennacchia, Ilaria ^c   Perracchio, Letizia ^a   Buglioni, Simonetta ^a   Ercolani, Cristiana ^a   Sperati, Francesca ^a   Costarelli, Leopoldo ^d   Bonanno, Elena ^e   Baldini, Daniela ^f   Candia, Silvia ^g   Crescenzi, Anna ^h   Dal Mas, Antonella ⁱ   Di Cristofano, Claudio ^j   Gomes, Vito ^k   Grillo, Lucia Rosalba ^l   Pasquini, Paola ^m   Pericoli, Maria Nicoletta ⁿ   Ramieri, Maria Teresa ^o   Di Stefano, Domenica ^p   Ruco, Luigi ^p   Scarpino, Stefania ^p   Vitolo, Domenico ^j   D'Amati, Giulia ^j   Paradiso, Angelo ^q   Verderio, Paolo ^b   Mottolese, Marcella ^a   more..

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f SAN FILIPPO NERI HOSPITAL   (Italy)

^g SANDRO PERTINI HOSPITAL   (Italy)

^h REGINA APOSTOLORUM HOSPITAL   (Italy)

ⁱ SAN SALVATORE HOSPITAL   (Italy)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k BELCOLLE HOSPITAL   (Italy)

^l SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^m Pathology Department   (Italy)

ⁿ SANTA MARIA GORETTI HOSPITAL   (Italy)

^o ASL Frosinone   (Italy)

^p SAPIENZA UNIVERSITY OF ROME   (Italy)

^q NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

more..

Author keywords

Breast Neoplasm drug therapy; Immunohistochemistry methods; Quality control; Receptor erbB 2 analysis; Reproducibility of results

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DISEASE MARKER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; QUALITY CONTROL; REFERENCE VALUE; REPRODUCIBILITY;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; QUALITY CONTROL; QUESTIONNAIRES; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS;

EID: 84882351787     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-58     Document Type: Article

References (26)

1. Treatment of HER2-positive breast cancer: current status and future perspectives. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L, Nat Rev Clin Oncol 2011 9 16 32 10.1038/nrclinonc.2011.177 22124364
2. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D, N Engl J Med 2006 355 2733 2743 10.1056/NEJMoa064320 17192538 (Pubitemid 46021510)
3. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM, CLEOPATRA Study Group, N Engl J Med 2012 366 109 119 10.1056/NEJMoa1113216 22149875
4. Trastuzumab emtansine for HER2-positive advanced breast cancer. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K, EMILIA Study Group, N Engl J Med 2012 367 1783 1791 10.1056/NEJMoa1209124 23020162
5. HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. English DP, Roque DM, Santin AD, Mol Diagn Ther 2013 17 85 99 10.1007/s40291-013-0024-9 23529353
6. Anti-HER-2 engineering antibody ChA21 inhibits growth and induces apoptosis of SK-OV-3 cells. AnLi Z, Hua X, XiaoGuang L, Yi G, Feng Y, LianSheng C, Jing L, Qiang W, J Exp Clin Cancer Res 2010 29 23 10.1186/1756-9966-29-23 20214830
7. American Society of Clinical Oncology/College of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology; College of American Pathologists, J Clin Onco 2007 25 118 145 (Pubitemid 350003059)
8. Adjuvant/neoadjuvant trastuzumab therapy in women with HER2/neu-overexpressing breast cancer: a systematic review. Madarnas Y, Trudeau M, Franek JA, McCready D, Pritchard KI, Messersmith H, Cancer Treat Rev 2008 34 539 557 10.1016/j.ctrv.2008.03.013 18502589
9. First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer: a preliminary report. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Eur J Cancer 2001 37 Suppl 1 25 29 11342197
10. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L, N Engl J Med 2001 344 783 792 10.1056/NEJM200103153441101 11248153 (Pubitemid 32222155)
11. Controversies in testing for HER2. Viale G, 2011 ASCO Annual Meeting Educational Book 2011 doi:1092-9118/10/1-10
12. A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer. Di Palma S, Collins N, Bilous M, Sapino A, Mottolese M, Kapranos N, Schmitt F, Isola J, J Clin Pathol 2008 61 757 760 18326010 (Pubitemid 351859970)
13. Conference summary, strategic science symposium. HER2/neu testing of breast cancer patients in clinical practice. Zarbo RJ, Hammond ME, Arch Pathol Lab Med 2003 127 549 553 12708896 (Pubitemid 36534937)
14. Guidelines for HER2 testing in the UK. Hsi ED, Tubbs RR, J Clin Pathol 2004 57 241 242 10.1136/jcp.2003.009308 14990591 (Pubitemid 38338832)
15. Best practice No 176: updated recommendations for HER2 testing in the UK. Ellis IO, Bartlett J, Dowsett M, Humphreys S, Jasani B, Miller K, Pinder SE, Rhodes A, Walker R, J Clin Pathol 2004 57 233 237 10.1136/jcp.2003.007724 14990588 (Pubitemid 38338829)
16. Interobserver reproducibility of immunohistochemical HER2/neu evaluation in human breast cancer: the real-world experience. Group INQAT, Int J Biol Markers 2004 19 147 154 15255548
17. Interobserver reproducibility of immunohistochemical HER2/neu assessment in human breast cancer: an update from INQAT round III. INQAT Group, Int J Biol Markers 2005 20 189 194 16240847
18. The need for a quality control of the whole process of immunohistochemistry human epidermal growth factor receptor 2/neu determination: a United Kingdom National External Quality Assessment Service/Italian Network for quality assessment of tumor biomarkers pilot experience. Paradiso A, Miller K, Marubini E, Pizzamiglio S, Verderio P, J Clin Oncol 2007 25 27 e28 10.1200/JCO.2006.10.5155 17664462
19. Fleiss JL, Statistical methods for rates and proportions New York: Wiley and Sons 2 1981
20. Jackknifing functions of multinomial frequencies, with an application to a measure of concordance. Fleiss JL, Davies M, Am J Epidemiol 1982 115 841 845 7091143 (Pubitemid 12076941)
21. Reproducibility in the diagnosis of needle core biopsies of non-palpable breast lesions: an international study using virtual slides published on the world-wide web. Zito FA, Verderio P, Simone G, Angione V, Apicella P, Bianchi S, Conde AF, Hameed O, Ibarra J, Leong A, Pennelli N, Pezzica E, Vezzosi V, Ventrella V, Pizzamiglio S, Paradiso A, Ellis I, Histopathology 2010 56 720 726 10.1111/j.1365-2559.2010.03548.x 20546337
22. Evaluation of residual cellularity and proliferation on preoperatively treated breast cancer: a comparison between image analysis and light microscopy analysis. Corletto V, Verderio P, Giardini R, Cipriani S, Di Palma S, Rilke F, Anal Cell Pathol 1998 16 83 93 9692682 (Pubitemid 28218615)
23. The measurement of observer agreement for categorical data. Landis R, Koch G, Biometrics 1977 33 117 127
24. Standardization of HER2 testing: results of an international proficiency-testing ring study. Dowsett M, Hanna WM, Kockx M, Penault-Llorca F, Rüschoff J, Gutjahr T, Habben K, van de Vijver MJ, Mod Pathol 2007 20 584 591 10.1038/modpathol.3800774 17396141 (Pubitemid 46632000)
25. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Fabi A, Di Benedetto A, Metro G, Perracchio L, Nisticò C, Di Filippo F, Ercolani C, Ferretti G, Melucci E, Buglioni S, Sperduti I, Papaldo P, Cognetti F, Mottolese M, Clin Cancer Res 2011 17 2055 2064 10.1158/1078-0432.CCR-10-1920 21307144
26. External quality assurance of HER2 FISH and ISH testing: three years of the UK national external quality assurance scheme. Bartlett JM, Ibrahim M, Jasani B, Morgan JM, Ellis I, Kay E, Connolly Y, Campbell F, O'Grady A, Barnett S, Miller K, Am J Clin Pathol 2009 131 106 111 10.1309/AJCPLN78ZQXEMNMA 19095573